Clinical trials: Oral Cancers
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study of CEP-701 in Treatment of Prostate Cancer
The purpose of this study is to determine the proportion of patients with a serological prostate specific antigen (PSA) by day 85.
- Trial name
- NCT00081601
- Testing
- CEP-701
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cephalon
Glioblastoma, Giant Cell Glioblastoma
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
The purpose of this study is to determine the highest safe dose of XL184 administered orally in combination with temozolomide (TMZ, Temodar®) and radiation therapy (RT).
- Conditions
- Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- NCT00960492
- Testing
- XL184, temozolomide, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Exelixis
Cervical Carcinoma Stage II, Cervical Carcinoma Stage III
Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and…
- Conditions
- Cervical Carcinoma Stage II, Cervical Carcinoma Stage III, Cervical Carcinoma Stage IV, Endometrial Adenocarcinoma Stage II
- Trial name
- NCT03540407
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 66 people
- Sponsor
- Catalysis SL
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Advanced Solid Tumors, Lymphoma
Phase I Trial of PX-478
This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer.
- Trial name
- NCT00522652
- Testing
- PX-478
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cascadian Therapeutics Inc.
Breast Cancer
A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
This phase 2 study will determine the antitumor activity, based on the objective rate, of oral MKC-1, administered twice daily for 14 consecutive days every 4 weeks, in patients with advanced or metastatic breast carcinoma.
- Trial name
- NCT00306631
- Testing
- MKC-1
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- CASI pharmaceuticals, Inc.
Malignant PEComa (Perivascular Epithelioid Cell Tumors)
A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa
Study objectives: The primary objective is to determine the efficacy of BEZ235 on Objective Response Rate (best response on study) according to RECIST 1.1 criteria The secondary objectives are: To determine the progression free…
- Trial name
- NCT01690871
- Testing
- BEZ235
- Where
- Spain
- Sponsor
- Novartis Pharmaceuticals
Advanced Cancer, Advanced Solid Tumor
Oral Administration of STC-15 in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer
- Trial name
- NCT05584111
- Testing
- STC-15
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- STORM Therapeutics LTD
Breast Cancer, Colorectal Cancer
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
This randomized, open-label, two-way crossover study will evaluate the relative bioavailabilty and safety of capecitabine rapid disintegrating tablets (RDT) versus commercial Xeloda tablets in patients with colorectal or breast…
- Trial name
- NCT01493336
- Testing
- capecitabine RTD, capecitabine [Xeloda]
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 37 people
- Sponsor
- Hoffmann-La Roche
Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line…
- Trial name
- NCT01289041
- Testing
- BKM120
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Safety Study of SLC-391 in Subjects With Solid Tumors
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties.
- Trial name
- NCT03990454
- Testing
- SLC-391
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- SignalChem Lifesciences Corporation
Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma…
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, Mantle Cell Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT01397825
- Testing
- Alisertib (MLN8237), Rituximab, Vincristine
- Where
- 25 sites in United States, Italy and 2 more
- Volunteers
- 45 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer
The primary objective was to determine the safety, tolerability and maximum tolerate dose (MTD) of BIBF 1120 in combination with pemetrexed.
- Trial name
- NCT02182102
- Testing
- BIBF 1120, Pemetrexed
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer
A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
Part A of this study will investigate the Maximum Tolerated Dose of Debio 0932 in combination with standard of care chemotherapy for the first- and second-line treatment of advanced NSCLC.
- Trial name
- HALO (NCT01714037)
- Testing
- Debio 0932, Cisplatin, Pemetrexed
- Where
- 8 sites in France, Spain and 1 more
- Volunteers
- 82 people
- Sponsor
- Debiopharm International SA
Chronic Lymphocytic Leukemia
A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Since in most cases CLL remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival.
- Trial name
- PROVIDENCE (NCT06125795)
- Where
- 25 sites in Spain
- Volunteers
- 146 people
- Sponsor
- AbbVie
Advanced Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors
The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors.
- Trial name
- NCT00842335
- Testing
- JI-101
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jubilant Innovation Ltd.
Solid Tumors
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
The purpose of this study is to evaluate the effect of trametinib once daily on the pharmacokinetics (PK) of a daily dosing oral contraceptives (OCs) containing norethindrone (NE) and ethinyl estradiol (EE) in female patients…
- Trial name
- NCT02705963
- Testing
- Trametinib, Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients…
- Trial name
- NCT03280030
- Testing
- Midostaurin
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.